BridgeBio Pharma, Inc. is set to announce its latest quarterly earnings on Monday, May 4th, with a consensus estimate EPS of -0.71.
BridgeBio Pharma, Inc. (BBIO) is currently trading at $73.19, experiencing a price decrease of $1.33 (-1.79%) from the previous close of $74.52. The trading volume is notably high at $5.64 million, representing a 225.05% increase relative to the average.
The latest quarterly earnings report for BBIO, announced on Monday, February 23rd, revealed a consensus estimate EPS of -0.75.
The cash flow statement indicates a net change in cash of -$72.41 million, with free cash flow at -$60.95 million and operating cash flow at -$56.42 million. Cash at the end of the period stands at $572.14 million.
BBIO reported revenue of $154.18 million, generating a gross profit of $138.76 million. Operating expenses totaled $324 million, resulting in a net income of -$197.24 million.
Key financial ratios for BBIO include a quick ratio of 2.52, operating profit margin at -120.14%, return on equity of 9.5%, and a price-to-sales ratio of 97.85.
The balance sheet reflects total assets of $936 million, with total liabilities at $3 billion. Net debt stands at $2.16 billion, indicating the company's financial position.
This report provides a snapshot of BridgeBio Pharma, Inc.'s financial performance and outlook for investors and stakeholders.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.